 Steven Ahrendt
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peritoneal Neoplasms | 24 | 2026 | 103 | 3.090 |
Why?
| | Hyperthermia, Induced | 22 | 2026 | 121 | 2.320 |
Why?
| | Cytoreduction Surgical Procedures | 16 | 2026 | 67 | 2.110 |
Why?
| | Pancreatic Neoplasms | 16 | 2024 | 928 | 1.440 |
Why?
| | Appendiceal Neoplasms | 13 | 2019 | 28 | 1.410 |
Why?
| | Pancreatectomy | 9 | 2024 | 285 | 1.000 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 16 | 2024 | 29 | 0.930 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 19 | 2026 | 1962 | 0.870 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2024 | 292 | 0.720 |
Why?
| | Neoadjuvant Therapy | 8 | 2026 | 463 | 0.690 |
Why?
| | Adenocarcinoma, Mucinous | 7 | 2020 | 76 | 0.640 |
Why?
| | Survival Rate | 25 | 2026 | 2100 | 0.600 |
Why?
| | Colorectal Neoplasms | 7 | 2026 | 849 | 0.550 |
Why?
| | Prognosis | 28 | 2026 | 4310 | 0.520 |
Why?
| | Combined Modality Therapy | 19 | 2026 | 1268 | 0.510 |
Why?
| | Hyperglycemia | 1 | 2020 | 376 | 0.470 |
Why?
| | Adenocarcinoma | 6 | 2024 | 931 | 0.430 |
Why?
| | Carcinoma, Signet Ring Cell | 4 | 2016 | 17 | 0.420 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2019 | 1148 | 0.410 |
Why?
| | Follow-Up Studies | 22 | 2026 | 5431 | 0.380 |
Why?
| | Stomach Neoplasms | 3 | 2024 | 128 | 0.370 |
Why?
| | Lung Neoplasms | 7 | 2019 | 2652 | 0.350 |
Why?
| | Mesothelioma | 3 | 2016 | 49 | 0.320 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2026 | 425 | 0.290 |
Why?
| | Biomarkers, Tumor | 4 | 2015 | 1325 | 0.290 |
Why?
| | Neoplasm Staging | 13 | 2022 | 1470 | 0.290 |
Why?
| | Middle Aged | 40 | 2026 | 36021 | 0.290 |
Why?
| | Neoplasm Grading | 9 | 2015 | 310 | 0.290 |
Why?
| | Retrospective Studies | 21 | 2026 | 17149 | 0.280 |
Why?
| | Genes, p53 | 3 | 2003 | 67 | 0.270 |
Why?
| | Cholangitis, Sclerosing | 2 | 1999 | 60 | 0.270 |
Why?
| | Lymphatic Metastasis | 9 | 2024 | 335 | 0.270 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2003 | 1183 | 0.270 |
Why?
| | Fluorouracil | 3 | 2024 | 235 | 0.260 |
Why?
| | Postoperative Complications | 7 | 2025 | 2938 | 0.260 |
Why?
| | Prospective Studies | 19 | 2025 | 8011 | 0.260 |
Why?
| | Bile Duct Neoplasms | 2 | 2018 | 130 | 0.250 |
Why?
| | Aged | 28 | 2026 | 26001 | 0.250 |
Why?
| | Endophytes | 1 | 2026 | 8 | 0.240 |
Why?
| | Survival Analysis | 8 | 2016 | 1386 | 0.240 |
Why?
| | Poaceae | 1 | 2026 | 61 | 0.230 |
Why?
| | Laparoscopy | 2 | 2021 | 477 | 0.230 |
Why?
| | Smad4 Protein | 1 | 2005 | 34 | 0.230 |
Why?
| | Neoplasms, Second Primary | 1 | 2026 | 100 | 0.220 |
Why?
| | Male | 43 | 2026 | 72629 | 0.220 |
Why?
| | Genes, ras | 3 | 2002 | 96 | 0.210 |
Why?
| | Fungi | 1 | 2026 | 161 | 0.210 |
Why?
| | Mutation | 6 | 2014 | 4104 | 0.210 |
Why?
| | Urologic Surgical Procedures | 1 | 2025 | 115 | 0.210 |
Why?
| | Female | 43 | 2026 | 78605 | 0.200 |
Why?
| | Antineoplastic Agents | 4 | 2021 | 2202 | 0.200 |
Why?
| | Thymidylate Synthase | 1 | 2003 | 13 | 0.200 |
Why?
| | Armillaria | 1 | 2023 | 3 | 0.200 |
Why?
| | Coelomomyces | 1 | 2023 | 1 | 0.200 |
Why?
| | Anopheles | 1 | 2023 | 18 | 0.200 |
Why?
| | Lentinula | 1 | 2023 | 1 | 0.200 |
Why?
| | Humans | 52 | 2026 | 145307 | 0.190 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2003 | 105 | 0.190 |
Why?
| | Parasites | 1 | 2023 | 44 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 557 | 0.190 |
Why?
| | Carcinoma | 3 | 2015 | 228 | 0.180 |
Why?
| | Pancreaticoduodenectomy | 2 | 2021 | 135 | 0.180 |
Why?
| | Adaptation, Physiological | 1 | 2026 | 572 | 0.180 |
Why?
| | CA-19-9 Antigen | 3 | 2022 | 34 | 0.170 |
Why?
| | Proportional Hazards Models | 6 | 2022 | 1328 | 0.170 |
Why?
| | Pancreatic Cyst | 1 | 2002 | 50 | 0.170 |
Why?
| | Nomograms | 1 | 2022 | 59 | 0.170 |
Why?
| | Cyclins | 1 | 2000 | 84 | 0.160 |
Why?
| | Body Composition | 1 | 2024 | 708 | 0.160 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 18 | 0.160 |
Why?
| | Neuroendocrine Tumors | 1 | 2002 | 114 | 0.160 |
Why?
| | Genome, Fungal | 2 | 2026 | 42 | 0.150 |
Why?
| | Databases, Factual | 2 | 2024 | 1488 | 0.150 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 84 | 0.150 |
Why?
| | Pseudomyxoma Peritonei | 1 | 2019 | 5 | 0.150 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 1999 | 63 | 0.150 |
Why?
| | Adult | 21 | 2026 | 40627 | 0.140 |
Why?
| | Pleural Neoplasms | 1 | 2019 | 29 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 6 | 2016 | 967 | 0.140 |
Why?
| | Aged, 80 and over | 10 | 2021 | 8295 | 0.140 |
Why?
| | Cholangiocarcinoma | 1 | 1999 | 108 | 0.130 |
Why?
| | Adenoma | 1 | 2020 | 218 | 0.130 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 697 | 0.130 |
Why?
| | Treatment Outcome | 10 | 2025 | 11731 | 0.130 |
Why?
| | Patient Compliance | 1 | 2021 | 589 | 0.130 |
Why?
| | Wearable Electronic Devices | 1 | 2018 | 63 | 0.130 |
Why?
| | Genomics | 2 | 2026 | 842 | 0.120 |
Why?
| | Carcinoid Tumor | 1 | 2016 | 21 | 0.120 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2016 | 70 | 0.120 |
Why?
| | Sequence Analysis, DNA | 2 | 2016 | 824 | 0.120 |
Why?
| | Depression | 2 | 2016 | 1561 | 0.110 |
Why?
| | Bile | 1 | 1994 | 26 | 0.110 |
Why?
| | Telomerase | 1 | 1997 | 249 | 0.110 |
Why?
| | Glucose | 1 | 2020 | 1049 | 0.110 |
Why?
| | Pancreatic Fistula | 1 | 2014 | 35 | 0.110 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2014 | 9 | 0.110 |
Why?
| | Learning Curve | 1 | 2014 | 70 | 0.100 |
Why?
| | Age Factors | 4 | 2022 | 3339 | 0.100 |
Why?
| | Microsporidia | 1 | 2013 | 2 | 0.100 |
Why?
| | Immunohistochemistry | 4 | 2016 | 1718 | 0.100 |
Why?
| | Chytridiomycota | 1 | 2013 | 28 | 0.100 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2014 | 104 | 0.100 |
Why?
| | DNA, Fungal | 1 | 2013 | 83 | 0.100 |
Why?
| | Inpatients | 1 | 2018 | 551 | 0.100 |
Why?
| | Phylogeny | 3 | 2026 | 1020 | 0.100 |
Why?
| | Walking | 1 | 2018 | 545 | 0.090 |
Why?
| | CA-125 Antigen | 1 | 2012 | 13 | 0.090 |
Why?
| | Cholesterol | 1 | 1994 | 408 | 0.090 |
Why?
| | Appendectomy | 1 | 2013 | 89 | 0.090 |
Why?
| | Patient Readmission | 1 | 2018 | 760 | 0.090 |
Why?
| | Carcinoembryonic Antigen | 2 | 2024 | 39 | 0.090 |
Why?
| | Gastrectomy | 1 | 2013 | 161 | 0.090 |
Why?
| | Fatigue | 1 | 2014 | 366 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2003 | 758 | 0.080 |
Why?
| | Leucovorin | 2 | 2024 | 101 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2014 | 2118 | 0.080 |
Why?
| | Sarcoma | 1 | 2013 | 205 | 0.080 |
Why?
| | Disease-Free Survival | 3 | 2013 | 771 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2014 | 427 | 0.080 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 409 | 0.080 |
Why?
| | Morbidity | 3 | 2016 | 324 | 0.070 |
Why?
| | Registries | 1 | 2018 | 2398 | 0.070 |
Why?
| | Mitomycin | 3 | 2013 | 32 | 0.070 |
Why?
| | Quality of Life | 2 | 2019 | 3197 | 0.070 |
Why?
| | Cisplatin | 3 | 2016 | 336 | 0.070 |
Why?
| | Sex Factors | 2 | 2022 | 2115 | 0.070 |
Why?
| | Lung Diseases | 1 | 2014 | 790 | 0.060 |
Why?
| | Lymph Nodes | 2 | 2002 | 502 | 0.060 |
Why?
| | Alternaria | 1 | 2026 | 9 | 0.060 |
Why?
| | Antarctic Regions | 1 | 2026 | 27 | 0.060 |
Why?
| | Antineoplastic Protocols | 1 | 2025 | 6 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 510 | 0.060 |
Why?
| | Thymidine Phosphorylase | 1 | 2005 | 14 | 0.060 |
Why?
| | Peritoneum | 1 | 2025 | 45 | 0.060 |
Why?
| | Injections, Intraperitoneal | 2 | 2016 | 117 | 0.060 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 49 | 0.060 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2005 | 26 | 0.060 |
Why?
| | Infusions, Parenteral | 2 | 2016 | 44 | 0.050 |
Why?
| | Microcirculation | 1 | 2005 | 145 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2005 | 223 | 0.050 |
Why?
| | Polymerase Chain Reaction | 3 | 2016 | 1054 | 0.050 |
Why?
| | Biomarkers | 2 | 2014 | 4284 | 0.050 |
Why?
| | Cold Temperature | 1 | 2026 | 210 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1540 | 0.050 |
Why?
| | Anthropometry | 1 | 2024 | 200 | 0.050 |
Why?
| | Crustacea | 1 | 2023 | 5 | 0.050 |
Why?
| | Risk Assessment | 3 | 2016 | 3686 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2005 | 237 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 22507 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 392 | 0.050 |
Why?
| | Dideoxynucleosides | 1 | 2003 | 24 | 0.050 |
Why?
| | Gene Transfer, Horizontal | 1 | 2023 | 35 | 0.050 |
Why?
| | Agaricus | 1 | 2023 | 3 | 0.050 |
Why?
| | Pennsylvania | 2 | 2014 | 138 | 0.050 |
Why?
| | Thailand | 1 | 2023 | 18 | 0.050 |
Why?
| | Young Adult | 5 | 2022 | 14163 | 0.050 |
Why?
| | Biomass | 1 | 2023 | 116 | 0.050 |
Why?
| | Time Factors | 3 | 2025 | 7186 | 0.050 |
Why?
| | Inflammation | 1 | 2014 | 2881 | 0.050 |
Why?
| | Genetic Markers | 1 | 2003 | 332 | 0.050 |
Why?
| | Larva | 1 | 2023 | 244 | 0.050 |
Why?
| | Risk Factors | 3 | 2024 | 10816 | 0.040 |
Why?
| | Intraoperative Care | 1 | 2002 | 62 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2002 | 183 | 0.040 |
Why?
| | Liver Transplantation | 2 | 1999 | 827 | 0.040 |
Why?
| | Plants | 1 | 2023 | 226 | 0.040 |
Why?
| | Regression Analysis | 1 | 2003 | 1003 | 0.040 |
Why?
| | Obesity | 1 | 2014 | 3085 | 0.040 |
Why?
| | Tumor Burden | 1 | 2022 | 323 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2022 | 239 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 112 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2024 | 653 | 0.040 |
Why?
| | Actuarial Analysis | 1 | 1999 | 21 | 0.040 |
Why?
| | Perioperative Care | 1 | 2002 | 232 | 0.040 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 1999 | 20 | 0.040 |
Why?
| | Neoplasms | 1 | 2014 | 2887 | 0.040 |
Why?
| | France | 1 | 2018 | 40 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1260 | 0.030 |
Why?
| | Ecosystem | 1 | 2023 | 590 | 0.030 |
Why?
| | DNA Methylation | 1 | 2003 | 686 | 0.030 |
Why?
| | Dilatation | 1 | 1998 | 72 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 2024 | 785 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2003 | 1462 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 983 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2016 | 66 | 0.030 |
Why?
| | Microdissection | 1 | 2016 | 15 | 0.030 |
Why?
| | Cause of Death | 1 | 1999 | 474 | 0.030 |
Why?
| | Linear Models | 1 | 1999 | 854 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1992 | 0.030 |
Why?
| | Hepatectomy | 1 | 1999 | 276 | 0.030 |
Why?
| | Postoperative Period | 1 | 2018 | 354 | 0.030 |
Why?
| | Comorbidity | 1 | 2022 | 1661 | 0.030 |
Why?
| | Transcriptome | 1 | 2023 | 1046 | 0.030 |
Why?
| | Goblet Cells | 1 | 2016 | 22 | 0.030 |
Why?
| | Microsatellite Instability | 1 | 2016 | 54 | 0.030 |
Why?
| | DNA Mismatch Repair | 1 | 2016 | 53 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 1999 | 342 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2000 | 533 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2016 | 30 | 0.030 |
Why?
| | Camptothecin | 1 | 2016 | 140 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2015 | 200 | 0.030 |
Why?
| | Cholelithiasis | 1 | 1994 | 36 | 0.030 |
Why?
| | Micelles | 1 | 1994 | 40 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 1999 | 365 | 0.030 |
Why?
| | Chromogranins | 1 | 2014 | 13 | 0.030 |
Why?
| | Crystallization | 1 | 1994 | 146 | 0.030 |
Why?
| | Necrosis | 1 | 2015 | 244 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2014 | 52 | 0.030 |
Why?
| | Preoperative Period | 1 | 2014 | 149 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 434 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 631 | 0.020 |
Why?
| | Stents | 1 | 1998 | 557 | 0.020 |
Why?
| | Mortality | 1 | 2016 | 376 | 0.020 |
Why?
| | Cell Wall | 1 | 2013 | 61 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1077 | 0.020 |
Why?
| | Sarcoma, Synovial | 1 | 2013 | 20 | 0.020 |
Why?
| | Phospholipids | 1 | 1994 | 214 | 0.020 |
Why?
| | ras Proteins | 1 | 2014 | 151 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2013 | 28 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2014 | 529 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 253 | 0.020 |
Why?
| | Liposarcoma | 1 | 2013 | 31 | 0.020 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2013 | 40 | 0.020 |
Why?
| | Omentum | 1 | 2012 | 9 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 460 | 0.020 |
Why?
| | Incidence | 1 | 1999 | 2892 | 0.020 |
Why?
| | DNA Damage | 1 | 2015 | 430 | 0.020 |
Why?
| | Splenectomy | 1 | 2012 | 65 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2014 | 420 | 0.020 |
Why?
| | Length of Stay | 1 | 1998 | 1342 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2002 | 2745 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2012 | 139 | 0.020 |
Why?
| | United States | 2 | 2021 | 16051 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 624 | 0.020 |
Why?
| | Doxorubicin | 1 | 2013 | 398 | 0.020 |
Why?
| | Biopsy | 1 | 2014 | 1079 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1311 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2014 | 782 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1217 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2013 | 517 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2931 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2016 | 2053 | 0.020 |
Why?
| | Child | 2 | 1999 | 22712 | 0.020 |
Why?
| | Case-Control Studies | 1 | 1994 | 3613 | 0.020 |
Why?
| | Body Mass Index | 1 | 2014 | 2439 | 0.010 |
Why?
| | O(6)-Methylguanine-DNA Methyltransferase | 1 | 2003 | 6 | 0.010 |
Why?
| | Sulfites | 1 | 2003 | 9 | 0.010 |
Why?
| | Glutathione S-Transferase pi | 1 | 2003 | 10 | 0.010 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2003 | 20 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 73 | 0.010 |
Why?
| | Glutathione Transferase | 1 | 2003 | 100 | 0.010 |
Why?
| | Isoenzymes | 1 | 2003 | 299 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 6079 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2001 | 64 | 0.010 |
Why?
| | Animals | 1 | 2023 | 38180 | 0.010 |
Why?
| | Codon | 1 | 2001 | 94 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2003 | 1496 | 0.010 |
Why?
| | DNA | 1 | 2003 | 1467 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2001 | 3419 | 0.010 |
Why?
|
|
Ahrendt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|